$0.0926
Insights on Sintx Technologies Inc
Revenue is down for the last 2 quarters, 902.0K → 687.0K (in $), with an average decrease of 23.8% per quarter
Netprofit is up for the last 3 quarters, -3.19M → -886.0K (in $), with an average increase of 99.7% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.0% return, outperforming this stock by 134.9%
In the last 3 years, Boston Scientific Corp. has given 79.7% return, outperforming this stock by 179.6%
10.22%
Downside
Day's Volatility :20.71%
Upside
11.68%
77.11%
Downside
52 Weeks Volatility :98.87%
Upside
95.05%
Period | Sintx Technologies Inc | Index (Russel 2000) |
---|---|---|
3 Months | -34.79% | 0.0% |
6 Months | -75.69% | 0.0% |
1 Year | -93.87% | 0.0% |
3 Years | -99.94% | -20.1% |
Market Capitalization | 13.9M |
Book Value | $1.65 |
Earnings Per Share (EPS) | -3.13 |
Wall Street Target Price | 1.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -281.15% |
Return On Assets TTM | -49.09% |
Return On Equity TTM | -114.11% |
Revenue TTM | 2.6M |
Revenue Per Share TTM | 0.7 |
Quarterly Revenue Growth YOY | 17.9% |
Gross Profit TTM | 1.3M |
EBITDA | -11.3M |
Diluted Eps TTM | -3.13 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.09 |
EPS Estimate Next Year | -0.05 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.03 |
What analysts predicted
Upside of 1519.87%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 95.0K | ↓ 99.38% |
Net Income | -8.7M | ↓ 47.87% |
Net Profit Margin | -9.1K% | ↓ 8998.36% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 689.0K | ↑ 625.26% |
Net Income | -4.8M | ↓ 43.96% |
Net Profit Margin | -703.77% | ↑ 8403.6% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 594.0K | ↓ 13.79% |
Net Income | -7.3M | ↑ 50.81% |
Net Profit Margin | -1.2K% | ↓ 527.37% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 606.0K | ↑ 2.02% |
Net Income | -9.8M | ↑ 34.32% |
Net Profit Margin | -1.6K% | ↓ 389.82% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 601.0K | ↓ 0.83% |
Net Income | -16.5M | ↑ 67.86% |
Net Profit Margin | -2.7K% | ↓ 1122.63% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.6M | ↑ 337.1% |
Net Income | -8.3M | ↓ 49.91% |
Net Profit Margin | -314.39% | ↑ 2429.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 247.0K | ↑ 42.77% |
Net Income | -8.4M | ↑ 216.69% |
Net Profit Margin | -3.4K% | ↓ 1869.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 240.0K | ↓ 2.83% |
Net Income | 3.0M | ↓ 135.31% |
Net Profit Margin | 1.2K% | ↑ 4641.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 235.0K | ↓ 2.08% |
Net Income | -2.5M | ↓ 182.69% |
Net Profit Margin | -1.0K% | ↓ 2281.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 678.0K | ↑ 188.51% |
Net Income | -3.2M | ↑ 29.94% |
Net Profit Margin | -470.5% | ↑ 574.18% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 902.0K | ↑ 33.04% |
Net Income | -2.3M | ↓ 27.24% |
Net Profit Margin | -257.32% | ↑ 213.18% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 687.0K | ↓ 23.84% |
Net Income | -886.0K | ↓ 61.83% |
Net Profit Margin | -128.97% | ↑ 128.35% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 11.5M | ↓ 56.15% |
Total Liabilities | 3.1M | ↓ 73.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 9.1M | ↓ 20.56% |
Total Liabilities | 3.9M | ↑ 26.6% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 30.4M | ↑ 232.86% |
Total Liabilities | 4.6M | ↑ 17.69% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 21.8M | ↓ 28.27% |
Total Liabilities | 4.1M | ↓ 11.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 15.8M | ↓ 27.78% |
Total Liabilities | 10.1M | ↑ 144.87% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 15.4M | ↓ 2.59% |
Total Liabilities | 6.6M | ↓ 34.52% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 15.8M | ↑ 8.31% |
Total Liabilities | 10.1M | ↑ 95.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 22.7M | ↑ 43.61% |
Total Liabilities | 6.7M | ↓ 33.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 19.1M | ↓ 15.69% |
Total Liabilities | 5.3M | ↓ 21.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.5M | ↓ 18.78% |
Total Liabilities | 4.8M | ↓ 8.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.4M | ↓ 0.95% |
Total Liabilities | 6.6M | ↑ 36.7% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 17.6M | ↑ 14.29% |
Total Liabilities | 7.6M | ↑ 15.8% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 30.38% |
Investing Cash Flow | -145.0K | ↓ 87.25% |
Financing Cash Flow | 14.4M | ↑ 347.65% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.4M | ↓ 31.16% |
Investing Cash Flow | 1.4M | ↓ 1052.41% |
Financing Cash Flow | 1.4M | ↓ 90.32% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.1M | ↑ 41.6% |
Investing Cash Flow | 1.8M | ↑ 26.79% |
Financing Cash Flow | 30.9M | ↑ 2118.44% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.1M | ↑ 11.19% |
Investing Cash Flow | -1.7M | ↓ 194.29% |
Financing Cash Flow | 705.0K | ↓ 97.72% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.3M | ↑ 1.29% |
Investing Cash Flow | -1.1M | ↓ 33.31% |
Financing Cash Flow | 3.3M | ↑ 373.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 15.26% |
Investing Cash Flow | -296.0K | ↓ 41.96% |
Financing Cash Flow | 3.8M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.9M | ↑ 133.85% |
Investing Cash Flow | -236.0K | ↓ 20.27% |
Financing Cash Flow | 11.5M | ↑ 198.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.2M | ↓ 34.31% |
Investing Cash Flow | -98.0K | ↓ 58.47% |
Financing Cash Flow | -88.0K | ↓ 100.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↓ 8.87% |
Investing Cash Flow | -105.0K | ↑ 7.14% |
Financing Cash Flow | -88.0K | ↑ 0.0% |
Sell
Neutral
Buy
Sintx Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Sintx Technologies Inc | 140.26% | -75.69% | -93.87% | -99.94% | -99.98% |
Stryker Corporation | 0.86% | 12.4% | 15.49% | 28.53% | 77.74% |
Boston Scientific Corp. | 11.25% | 36.51% | 40.96% | 76.8% | 100.56% |
Edwards Lifesciences Corp. | 3.89% | 34.72% | 1.32% | -5.35% | 56.97% |
Abbott Laboratories | -3.84% | 0.25% | -4.89% | -12.22% | 35.01% |
Medtronic Plc | 5.71% | 8.68% | -4.84% | -33.51% | -4.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Sintx Technologies Inc | NA | NA | NA | -0.09 | -1.14 | -0.49 | NA | 1.65 |
Stryker Corporation | 37.6 | 37.6 | 2.92 | 11.96 | 0.19 | 0.07 | 0.01 | 50.33 |
Boston Scientific Corp. | 63.33 | 63.33 | 1.8 | 2.33 | 0.09 | 0.05 | NA | 13.56 |
Edwards Lifesciences Corp. | 38.77 | 38.77 | 5.19 | 2.76 | 0.21 | 0.12 | NA | 11.82 |
Abbott Laboratories | 32.15 | 32.15 | 5.99 | 4.63 | 0.15 | 0.06 | 0.02 | 22.31 |
Medtronic Plc | 26.83 | 26.83 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Sintx Technologies Inc | Buy | $13.9M | -99.98% | NA | 0.0% |
Stryker Corporation | Buy | $125.6B | 77.74% | 37.6 | 16.03% |
Boston Scientific Corp. | Buy | $110.8B | 100.56% | 63.33 | 12.05% |
Edwards Lifesciences Corp. | Buy | $54.4B | 56.97% | 38.77 | 23.01% |
Abbott Laboratories | Buy | $179.5B | 35.01% | 32.15 | 13.96% |
Medtronic Plc | Buy | $112.2B | -4.04% | 26.83 | 13.0% |
Vanguard Group Inc
Geode Capital Management, LLC
State Street Corporation
Virtu Financial LLC
TWO SIGMA SECURITIES, LLC
KESTRA PRIVATE WEALTH SERVICES, LLC
amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.
Organization | Sintx Technologies Inc |
Employees | 43 |
CEO | Dr. B. Sonny Bal J.D., M.B.A., M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.09
+1.42%
Keyarch Acquisition Corp
$0.09
+1.42%
Connexa Sports Technologies Inc
$0.09
+1.42%
Us Value Etf
$0.09
+1.42%
First Wave Biopharma Inc
$0.09
+1.42%
Global X Msci Next Emerging
$0.09
+1.42%
Fat Projects Acquisition Corp
$0.09
+1.42%
Ishares Intl Div Growth Etf
$0.09
+1.42%
Corsair Gaming, Inc.
$0.09
+1.42%